Catecholamine receptor modulation
AssigneeYeda Research and Development Co. Ltd.
InventorsTsvee Lapidot, Asaf Spiegel, Menachem Rubinstein, Alexander Kalinkovich, Shoham Shivtiel
Life of this patent
Estimating the term…
Abstract
The invention relates to receptors of catecholamines and their role in stem cell development and function.
Claims20
An isolated cell population comprising:
- a) CD34+ hematopoietic stem cells and/or progenitors suitable for transplantation therapy stimulated ex-vivo with a composition comprising a catecholamine receptor agonist;
- or
- b) CD34+ hematopoietic stem cells and/or progenitors suitable for transplantation therapy stimulated ex-vivo with a composition comprising a catecholamine receptor agonist in combination with an agent capable of up-regulating the expression level of the catecholamine receptor in the stem cells or progenitors.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a population of cells comprising:
- a) CD34+ hematopoietic stem cells and/or progenitors suitable for transplantation therapy stimulated ex-vivo with a composition comprising a catecholamine receptor agonist;
- or
- b) CD34+ hematopoietic stem cells and/or progenitors suitable for transplantation therapy stimulated ex-vivo with a composition comprising a catecholamine receptor agonist in combination with an agent capable of up-regulating the expression level of the catecholamine receptor in the stem cells or progenitors.
A method of stem cell transplantation (SCT) and/or progenitor transplantation therapy comprising administering to a patient in need a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and:
- a) CD34+ hematopoietic stem cells and/or progenitors suitable for transplantation therapy stimulated ex-vivo with a composition comprising a catecholamine receptor agonist;
- or
- b) CD34+ hematopoietic stem cells and/or progenitors suitable for transplantation therapy stimulated ex-vivo with a composition comprising a catecholamine receptor agonist in combination with an agent capable of up-regulating the expression level of the catecholamine receptor in the stem cells or progenitors, said CD34+ hematopoietic stem cells and/or progenitors comprising autologous CD34+ hematopoietic stem cells and/or progenitors from said patient.
A method of stem cell transplantation (SCT) and/or progenitor cell transplantation therapy comprising administering to a patient in need an agent that up-regulates expression of the catecholamine receptor of said stem cells and/or progenitor cells in combination with a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and:
- a) CD34+ hematopoietic stem cells and/or progenitors suitable for transplantation therapy stimulated ex-vivo with a composition comprising a catecholamine receptor agonist;
- or
- b) CD34+ hematopoietic stem cells and/or progenitors suitable for transplantation therapy stimulated ex-vivo with a composition comprising a catecholamine receptor agonist in combination with an agent capable of up-regulating the expression level of the catecholamine receptor in the stem cells or progenitors.
A method for tissue replacement, engraftment regeneration and/or repopulation therapy comprising transplanting into a patient in need a therapeutically effective amount of a cell population comprising:
- a) CD34+ hematopoietic stem cells and/or progenitors suitable for transplantation therapy stimulated ex-vivo with a composition comprising a catecholamine receptor agonist;
- or
- b) CD34+ hematopoietic stem cells and/or progenitors suitable for transplantation therapy stimulated ex-vivo with a composition comprising a catecholamine receptor agonist in combination with an agent capable of up-regulating the expression level of the catecholamine receptor in the stem cells or progenitors.
A method of stimulating a population of cells comprising contacting a cell population comprising hematopoietic stem cells and/or progenitors with a catecholamine receptor agonist in vitro.
Dependencies are inferred from the claim text.